This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardlytics, Inc. (CDLX) Q4 Earnings Top Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 125.00% and -0.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics, Inc. (CDLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verisk (VRSK) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Verisk's (VRSK) fourth-quarter 2019 earnings and revenues are likely to have increased year over year.
Top Ranked Momentum Stocks to Buy for January 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd
Will Cardlytics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cardlytics.
Here's Why Cardlytics, Inc. (CDLX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Cardlytics, Inc. (CDLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardlytics, Inc. (CDLX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cardlytics, Inc. (CDLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cardlytics, Inc. (CDLX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardlytics, Inc. (CDLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardlytics, Inc. (CDLX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 120.00% and 13.89%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Cardlytics, Inc. (CDLX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardlytics, Inc. (CDLX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cardlytics, Inc. (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cardlytics, Inc. (CDLX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 47.83% and 11.23%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cardlytics, Inc. (CDLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fiserv (FISV) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Fiserv's (FISV) second-quarter 2019 results to reflect revenue growth and better operating performance.
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) second-quarter 2019 results are likely to benefit from continued market penetration of analytics and technology-enabled offerings across the company's TAS and R&DS businesses.
Here's Why Momentum Investors Will Love Cardlytics, Inc. (CDLX)
by Zacks Equity Research
Does Cardlytics, Inc. (CDLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardlytics, Inc. (CDLX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Cardlytics, Inc. (CDLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
All You Need to Know About Cardlytics, Inc. (CDLX) Rating Upgrade to Strong Buy
by Zacks Equity Research
Cardlytics, Inc. (CDLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Moving Average Crossover Alert: Cardlytics
by Zacks Equity Research
Cardlytics, Inc. (CDLX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Cardlytics (CDLX) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Cardlytics (CDLX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Zacks.com featured highlights include: ADTRAN, Cardlytics, Molina and Carlisle
by Zacks Equity Research
Zacks.com featured highlights include: ADTRAN, Cardlytics, Molina and Carlisle
Bet on These 4 Top Liquid Stocks for Solid Returns
by Zacks Equity Research
Here are four impressive liquid stocks that are poised to offer marvelous returns.
New Strong Buy Stocks for May 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday:
Cardlytics, Inc. (CDLX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cardlytics, Inc. (CDLX).
Cardlytics, Inc. (CDLX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Cardlytics, Inc. (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).